Jeannette Potts
CIK: 0001814693
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
uniQure N.V.
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jun 15, 2026QURE
uniQure N.V.
Sale(S)Direct5.2K shares at avg. $27.67$145K - Mar 4, 2026QURE
uniQure N.V.
Award(A)Direct35.4K shares- - Mar 4, 2026QURE
uniQure N.V.
Sale(S)Direct3.4K shares at avg. $9.06$31K - Mar 2, 2026QURE
uniQure N.V.
Sale(S)Direct8.6K shares at avg. $9.95$85K - Jun 16, 2025QURE
uniQure N.V.
Sale(S)Direct4.7K shares at avg. $15.14$71K - Mar 4, 2025QURE
uniQure N.V.
Sale(S)Direct7.1K shares at avg. $10.29$73K - Mar 3, 2025QURE
uniQure N.V.
Award(A)Direct35K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 15, 2026 | QURE uniQure N.V. | Sale(S) | 5,237 | $27.67 | $144,908 | Direct |
| Mar 4, 2026 | QURE uniQure N.V. | Award(A) | 35,400 | - | $0 | Direct |
| Mar 4, 2026 | QURE uniQure N.V. | Sale(S) | 3,412 | $9.06 | $30,913 | Direct |
| Mar 2, 2026 | QURE uniQure N.V. | Sale(S) | 8,578 | $9.95 | $85,351 | Direct |
| Jun 16, 2025 | QURE uniQure N.V. | Sale(S) | 4,670 | $15.14 | $70,704 | Direct |
| Mar 4, 2025 | QURE uniQure N.V. | Sale(S) | 7,076 | $10.29 | $72,812 | Direct |
| Mar 3, 2025 | QURE uniQure N.V. | Award(A) | 35,000 | - | - | Direct |
1-7 of 7 transactions
About Potts Jeannette
Potts Jeannette (SEC CIK 0001814693) files insider reports with the SEC as Chief Legal Officer of uniQure N.V. (QURE).
Signal8 holds 5 ownership filings by Potts Jeannette, all Form 4s, filed between Mar 5, 2025 and Jun 17, 2026. Those filings report 7 transactions, from Mar 3, 2025 to Jun 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Potts Jeannette's filings is in AMSTERDAM.
Recent filings by Potts Jeannette
- Jun 15, 2026: Open-market sale of QURE shares (Form 4, code S).
- Mar 4, 2026: Grant or award of QURE shares (Form 4, code A).
- Mar 4, 2026: Open-market sale of QURE shares (Form 4, code S).
- Mar 2, 2026: Open-market sale of QURE shares (Form 4, code S).
- Jun 16, 2025: Open-market sale of QURE shares (Form 4, code S).
Other insiders filing for uniQure N.V. (QURE)
- Abi-Saab Walid, Chief Medical Officer
- Kapusta Matthew C, CEO, Managing Director
- Kaye Jack, Director
- Balachandran Madhavan, Director
- Meek David D., Director
- Gut Robert, Director